Delivery Order SPE2DB20D3103-SPE2DB24FQ0C9

Award Date 8/23/24
Potential Completion Date 8/26/24
Potential Value $9.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $61,266.45 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of the pharmaceutical product ENTRESTO 24 MG-26 MG TABLET 180S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military treatment programs and...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $12,161.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 180 tablets of the pharmaceutical product ENTRESTO 24 MG-26 MG. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as...
The U.S. Defense Logistics Agency (DLA) awarded a $10,582.47 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ENTRESTO 97 MG-103 MG tablets. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs...
The U.S. Defense Logistics Agency (DLA) awarded a $2,736.45 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ENTRESTO 49 MG-51 MG tablets, a medication used to treat cardiovascular conditions. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides...
The U.S. Defense Logistics Agency (DLA) awarded a $1,850.08 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which does not have a set-aside designation, is for the supply of ENTRESTO 24 MG-26 MG TABLET 180S, a cardiovascular medication. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product ENTRESTO 97 MG-103 MG TABLET 180S. The contract has a ceiling value of $2,384.62 and a period of performance through April 3, 2024. Amerisourcebergen Drug Corp serves as the prime contractor on this delivery order, which is issued under a larger indefinite delivery contract (IDC)...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,101.27 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ENTRESTO 97 MG-103 MG tablets. This order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract, valued at $11,384.48, is for the delivery of ENTRESTO 97 MG-103 MG tablets. This delivery order falls under Amerisourcebergen's larger indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 with a performance period through December...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,454.00 firm fixed-price delivery order is for the supply of the medication ENTRESTO 24 MG-26 MG TABLET 60S. The contract has an ultimate completion date of March 3, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $20,213.93 to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The contract, with a completion date of May 9, 2024, is for the delivery of 4564544245 units of the drug ENTRESTO 24 MG-26 MG TABLET 180S. This award is associated with Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB24FQ0C9
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $9,274.86 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, for the supply of 180 tablets of the drug ENTRESTO (97 mg-103 mg). This delivery order contract falls under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the agency to efficiently procure a wide range of medical commodities, including pharmaceuticals and supplies, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is scheduled for completion by August 26, 2024.

Generated 11/22/24, 9:36 AM